Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 100% portion size Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Varying the Energy Density and Portion Size of the Main Course After a First-course Salad

NCT01729390
View directory record Official record
Conditions
Obesity
Interventions
Energy density and portion size feeding study
Other
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 3, 2026, 8:36 AM EDT
Recruiting Phase 2 Interventional

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

NCT05763953
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Oak Lawn, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional

Effects of Portion Size of Multiple Items at a Meal on Food Intake of Adults

NCT02369588
View directory record Official record
Conditions
Feeding Behaviors
Interventions
Food portion size
Other
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional Results available

Variations in Palatability and Portion Size of Vegetables on Meal Intake of Preschool Children

NCT03926065
View directory record Official record
Conditions
Feeding Behavior
Interventions
Plain Vegetables Served in 100% Portion Size, Plain Vegetables Served in 200% Portion Size, Enhanced Vegetables Served in 100% Portion Size, Enhanced Vegetables Served in 200% Portion Size
Other
Lead sponsor
Penn State University
Other
Eligibility
3 Years to 5 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

NCT01750918
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 3, 2026, 8:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reading Outcomes in Children With Vestibular Loss

NCT05414903
View directory record Official record
Conditions
Vestibular Disorder, Hearing Loss, Sensorineural
Interventions
Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity
Behavioral
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
7 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional

Effect of Portion-control Training on Food Intake

NCT02942589
View directory record Official record
Conditions
Feeding Behaviors
Interventions
Meal portion size
Other
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 66 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

NCT02065063
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Palbociclib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 3, 2026, 8:36 AM EDT
Recruiting Phase 2 Interventional

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT05613413
View directory record Official record
Conditions
Metastatic Squamous Non-Small Cell Lung Carcinoma
Interventions
Pacliltaxel or Nab-paclitaxel, Carboplatin or Cisplatin, Pembrolizumab, Cabozantinib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individual Differences in Children's Susceptibility to Overeating

NCT01905293
View directory record Official record
Conditions
Obesity
Interventions
Feeding Study
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
8 Years to 10 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional Results available

Effect of Portion Size Over 5 Days in Preschool Children

NCT02963987
View directory record Official record
Conditions
Feeding Behavior
Interventions
Food and Beverage Portion Size
Other
Lead sponsor
Penn State University
Other
Eligibility
3 Years to 5 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeting Access and Knowledge of Earned Income Tax Credit (EITC) Utilization and Policies

NCT06146621
View directory record Official record
Conditions
Mental Health Issue, Food Security, Well-being
Interventions
Low-touch text messaging, Personal tax filing support, Information about free tax-filing support, Financial assistance
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional

The Influence of Satiation Measures on the Portion Size Effect

NCT03886428
View directory record Official record
Conditions
Feeding Behavior
Interventions
100% portion size, 125% portion size, 150% portion size, 175% portion size
Other
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Novel Approaches for Prevention

NCT01183689
View directory record Official record
Conditions
Weight Gain
Interventions
Small Behavior Changes, Large Behavior Changes
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 35 Years
Enrollment
599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 3, 2026, 8:36 AM EDT
Terminated Phase 1 Interventional

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

NCT02235740
View directory record Official record
Conditions
Cancer
Interventions
Afuresertib, Carfilzomib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 3, 2026, 8:36 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 3, 2026, 8:36 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

NCT05114798
View directory record Official record
Conditions
Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer
Interventions
Time restricted eating, Calorie Restriction
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years to 70 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 3, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional Results available

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

NCT03681951
View directory record Official record
Conditions
Neoplasms, Pancreatic
Interventions
GSK3145095, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 3, 2026, 8:36 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

A Highly Portable Device for Assessment of Mild Traumatic Brain Injury in Deployed and Far-Forward Settings

NCT05527041
View directory record Official record
Conditions
Concussion, Brain, Mild Traumatic Brain Injury
Interventions
EyeBOX Lens (EBLens)
Device
Lead sponsor
Oculogica, Inc.
Industry
Eligibility
17 Years to 35 Years
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Point, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 3, 2026, 8:36 AM EDT
Terminated Not applicable Interventional

The Role of Satiety in the Effect of Portion Size on Intake

NCT03409601
View directory record Official record
Conditions
Feeding Behavior
Interventions
100% Portion Size, 125% Portion Size, 150% Portion Size, 175% Portion Size
Other
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 3, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uro-NIRS Clinical Study

NCT00706407
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Fully integrated Uro-NIRS:UDS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 3, 2026, 8:36 AM EDT